Heron Therapeutics traded at $1.17 this Wednesday February 11th, decreasing $0.10 or 7.87 percent since the previous trading session. Looking back, over the last four weeks, Heron Therapeutics lost 21.48 percent. Over the last 12 months, its price fell by 29.52 percent. Looking ahead, we forecast Heron Therapeutics to be priced at 2.71 by the end of this quarter and at 2.47 in one year, according to Trading Economics global macro models projections and analysts expectations.
Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.